SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 14th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 14th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of February 13, 2023 (the “Purchase Agreement”). Capitalized terms used herein shall have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
OPTION AND ASSET PURCHASE AGREEMENT dated as of November 14, 2022 by and between RADIOMEDIX, INC. and FUSION PHARMACEUTICALS INC.Option and Asset Purchase Agreement • February 14th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and Asset Purchase Agreement (this “Agreement”), dated as of November 14, 2022, is entered into by and between Fusion Pharmaceuticals Inc., a Canadian federal corporation (“Buyer”), and RadioMedix, Inc., a Texas corporation (“Seller”). Seller and Buyer are sometimes referred to in this Agreement collectively as the “Parties” and individually as a “Party”.
